The maker of the allergy drug EpiPen racked up an increasing amount of money from taxpayer-funded government programs over the past five years, Sen. Chuck Grassley says.

The share of Mylan’s revenue from government programs such as Medicaid and Medicare rose 30 percentage points from 23.3 percent in 2011 to 53.4 percent in 2015, the Iowa Republican’s office found.